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Abstract
Background: Patients undergoing percutaneous coronary intervention (PCI) with drug-eluting stent 
(DES) on unprotected left main (ULM) represent a complex subset. The role of routine coronary angi-
ography at follow up in this subset remains debated.  
Methods: At the documented center, all patients undergoing successful PCI on ULM lesions perform-
ing angiographic follow-up is suggested, but adherence to such a recommendation is inhomogeneous. 
Consecutive patients undergoing DES PCI on ULM were enrolled and experienced no adverse events 
during the first 6 months. Patients were then allocated to two groups: those undergoing routine control 
angiography (CA) and those undergoing clinical follow-up (CF). Primary endpoint was major adverse 
cardiac events (MACE) defined as cardiac death, myocardial infarction and urgent repeat target vessel 
revascularization. 
Results: A total of 190 patients underwent successful DES implantation on ULM and the study popu-
lation was without early events. CA was performed at 6 months after the index procedure in 91 (48%) 
patients. After 35 ± 21 months, MACE rates were significantly more common in the CF group as com-
pared with the CA group (16.2% vs. 4.3%, p = 0.009). At multivariable analysis, CA was associated 
with reduced MACE risk (HR 0.13, 95% CI 0.1–0.7, p = 0.028). Of note, this was mainly driven by 
higher cardiac death rate in those undergoing CF than in those undergoing CA (p = 0.01).
Conclusions: CA after complex PCI, such as ULM PCI, is associated with reduced MACE. Such an 
observation calls for appropriately designed randomized trials. (Cardiol J 2018; 25, 5: 582–588)
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Introduction
Percutaneous coronary intervention (PCI) for 
complex lesions, such as unprotected left main 
(ULM) disease has improved over time. After 
successful PCI, controlled randomized studies 
comparing follow-up strategies are lacking. Routine 
control angiography is commonly used in studies 
assessing restenosis rate [1, 2]. Such an approach 
has been recognized to be associated with a detect-
able, albeit small, risk of morbidity and mortality 
[3–5]. Moreover, arguments in favor of repeat 
revascularization in the presence of asymptomatic 
restenosis are scarce [6] and the clinical impact of 
routine control angiography on long-term survival 
has been challenged [7–9]. On this basis, guideline-
writing authorities recommend a control angiogra-
phy after PCI in restricted clinical situations such 
as patients complaining of angina symptoms or 
presenting signs of ischemia [10]. Nevertheless, 
since patients with angiographically-proven reste-
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nosis have worse prognosis at long-term follow-up 
[11–13], when dealing with patients at higher risk, 
planned coronary angiography may be considered. 
In the present study, it was sought to assess 
the clinical impact of routine control angiography 
in patients undergoing successful PCI on complex 
lesions such as ULM diseases.
Methods
Study design
A retrospective observational study was con-
ducted which included consecutive patients who 
underwent successful PCI with drug-eluting stent 
(DES) implantation for ULM lesions at the docu-
mented center between January 2006 and Decem-
ber 2012. During the study period, in accordance 
with internal protocol at the present institution, pa-
tients undergoing successful PCI on ULM lesions 
were recommended to undergo routine control 
angiography at 6–9 months. However, adherence 
to our recommendation was inhomogeneous due 
to referring physician and patient preference. As 
a consequence, some patients only received coro-
nary angiography (CA) at follow up while the others 
underwent non-invasive clinical follow-up (CF).
Clinical and procedural characteristics were 
prospectively collected for each patient and entered 
into a dedicated catheterization laboratory database 
(Estensa, Esaote, Genoa, Italy). 
The left main coronary artery was defined as 
unprotected in the absence of previous coronary 
artery bypass grafting (CABG) and if CABG had 
been performed but grafts to the left coronary 
system were occluded. PCI was defined successful 
if a stent was implanted, visual final diameter ste-
nosis was ≤ 20% and a thrombolysis in myocardial 
infarction (TIMI) 3 flow in the treated segment. 
Pre and post-dilatation, kissing balloon dilatation, 
ventricular assistance and adjunctive intravascular 
imaging were used at the operator’s discretion. 
The study flow-chart is reported in Figure 1. 
Briefly, patients who had undergone successful 
PCI with DES implantation on ULM were first 
retrospectively identified. Then, patients with ad-
verse events occurring during the first 6 months 
were excluded. The selected study population was 
allocated into two groups: patients who received 
CA and those who underwent CF. 
For all patients enrolled, clinical records were 
carefully evaluated and clinical follow-up was 
obtained by outpatient visit (in patients who de-
cided to be followed-up at this Institution) or by 
telephone interview (for the remaining patients).
Study end-points
Primary composite endpoint was major ad-
verse cardiac events (MACE), defined as cardiac 
death, myocardial infarction (MI) and urgent repeat 
target vessel revascularization (TVR) occurring 
after 6 months during follow-up. 
Cardiac death was defined as any death without 
clear non-cardiac cause. MI during the follow-up 
was diagnosed according to clinical symptoms, 
Figure 1. Study flow-chart; CA — coronary angiography; CF — clinical follow-up; DES — drug-eluting stent; 
PCI — percutaneous coronary intervention; ULM — unprotected left main.
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electrocardiographic changes and elevation of car-
diac biomarkers as explained in the third universal 
definition [14]. 
Urgent TVR was defined as TVR occurring 
in the setting of an unplanned hospitalization due 
to documented or suspected acute myocardial 
ischemia.
Secondary end-points included the individual 
components of primary end-point and the com-
posite of cardiac death and MI. Another secondary 
end-point was any TVR including those performed 
at the time of planned CA. 
Statistical analyses
Continuous variables were expressed as mean 
± standard deviation, categorical data as n/N (%). 
The c2 or Fisher exact tests were used for categori-
cal variables. P value < 0.05 was considered signifi-
cant. Multivariable Cox proportional hazard model 
adjusted for potential confounding variables were 
used to assess the independent role of routine con-
trol angiography in the risk for MACE. The model 
included all clinical features reporting a difference 
between the two groups plus cardiovascular risk 
factors, age, sex, clinical presentation, number 
of diseased vessels, number of treated vessels, 
stent type and stent length. The rates of freedom 
from major events were constructed according to 
Kaplan and Meier, and comparisons were made 
using the log-rank test. The SPSS 18.0 statistical 
software (SPSS Italia, Inc., Firenze, Italia) was 
used for analyses.
Results 
The study flow-chart is reported in Figure 1. 
Out of 6349 patients who underwent elective PCI 
at the present institution during the study period, 
201 patients underwent elective ULM PCI and 
were eligible for the study. Eleven patients were 
then excluded: 7 died during the first 6 months and 
4 patients were lost to follow-up. Thus, a total of 
190 patients constituted the study population. Out 
of these, 91 (48%) patients had elective follow-
up coronary angiography and constituted the CA 
group while the remaining 99 (52%) constituted 
the CF group. 
Baseline clinical characteristics of the study 
groups are summarized in Table 1 showing the 
absence of significant differences in cardiovascular 
risk factors and cardiac clinical presentation. Simi-
larly, angiographic and procedural characteristics 
(Table 2) were similar between the right coronary 
artery and CF group except for a significantly 
Table 1. Baseline characteristics of the study groups. 
All  
(n = 190)
CA group  
(n = 91)
CF group  
(n = 99)
P  
(1 vs. 2)
Age [years] 69 ± 10 66 ± 10 71 ± 10 0.5
Male 155 (81%) 75 (82.4%) 80 (79.2%) 0.3
Risk factors:
Diabetes 55 (28.9%) 27 (29.7%) 28 (27.7%) 0.4
Hypertension 154 (81%) 71 (78.0%) 83 (82.2%) 0.3
Dislipidemia 117 (61.5%) 58 (63.7%) 59 (58.4%) 0.3
Current smokers 36 (18.9%) 17 (18.7%) 19 (18.8%) 0.6
Renal failure: 23 (12.1%) 8 (8.8%) 15 (14.9%) 0.2
History of MI 43 (22.6%) 15 (16.5%) 28 (27.7%) 0.05
Prior PCI 54 (28%) 26 (28.6%) 28 (27.7%) 0.5
Prior CABG 22 (11.5%) 9 (8.8%) 13 (12.9%) 0.3
Mild LVEF disfunction (EF 49–30) 27 (14.2%) 11 (12.1%) 16 (15.8%) 0.3
Severe LVEF disfunction (EF < 30) 17 (8.9%) 8 (8.8%) 9 (8.9%) 0.6
Admission diagnosis:
Stable angina 136 (71.7%) 68 (74.7%) 68 (68.7%) 0.15
NSTEMI 18 (9.4%) 7 (7.7%) 11 (10.9%) 0.3
Unstable angina 36 (18.9%) 16 (17.6%) 20 (20.4%) 0.5
CA — coronary angiography; CF — clinical follow-up; CABG — coronary artery bypass grafting; LVEF — left ventricular ejection fraction;  
MI — myocardial infarction; NSTEMI — non-ST-segment elevation myocardial infarction; PCI — percutaneous coronary intervention
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higher side-branch stenting (p = 0.003) in the CA 
group. After a mean of 35 ± 21 months, a total of 
20 (10.5%) patients experienced MACE (Table 3). 
MACE rates were significantly more frequent in 
the CF group than CA group (16.2% vs. 4.3%, p = 
0.009), mainly due to a significantly higher cardiac 
death rate (p = 0.01). The rates of urgent TVR 
and MI were similar in the two groups. Any TVR 
rate was significantly higher in the CA group than 
in the CF group (15.4% vs. 5% of CF, p = 0.014). 
Table 2. Procedural characteristics of the study groups. 
All  
(n = 190)
CA group  
(n = 91)
CF group  
(n = 99)
P  
(1 vs. 2)
Radial approach 145 (76.3%) 69 (75.8%) 76 (76.7%) 0.5
Contrast dose [mL] 338.4 ± 126 341.7 ± 125 335 ± 127 0.7
No of disease vessels:
1 vessel 69 (36.3%) 33 (36.2%) 36 (36.3%) 0.5
2 vessels 60 (31.6%) 28 (30.7%) 32 (32.3%) 0.5
3 vessels 53 (27.9%) 24 (26.3%) 29 (29.2%) 0.4
No. of treated vessel:
1 vessel 111 (58.4%) 49 (53.8%) 62 (62.3%) 0.4
2 vessels 59 (31%) 30 (32.9%) 29 (29.3%) 0.5
3 vessels 4 (2%) 2 (2.2%)   2 (2.0%) 0.4
Complete revascularization 141 (74%) 69 (75%) 72 (73%) 0.3
Assisted PCI (IABP or Impella) 16 (8.4%) 7 (7.6%)   9 (9.1%) 0.3
Intravascular imaging (IVUS or OCT) 49 (26%) 27 (29.7%) 22 (22.2%) 0.13
Stent length [mm] 27.8±13 28.6±13 27.1±14 0.5
Stent diameter [mm] 3.6±0.4 3.6±0.4 3.6±0.5 0.7
Multiple stents 38 (20%) 17 (19%) 21 (21%) 0.5
Bifurcation strategy
Side branch stenting 19 (10%) 15 (16.5%) 4 (4.0%) 0.003
TAP stenting 14 (7%) 10 (11%) 4 (4.0%) 0.055
Other side branch stenting technique 5 (2.6%) 5 (5.5%) 0 (0%) 0.023
Final kissing balloon 123 (64.7%) 59 (64.8%) 64 (64.4%) 0.5
CA — coronary angiography; CF — clinical follow-up; IABP — intra-aortic balloon pump; IVUS — intravascular ultrasound; OCT — optical  
coherence tomography; PCI — percutaneous coronary intervention; TAP — T-stenting and small protusion
Table 3. Clinical events during follow-up in the study group.
All  
(n = 190)
CA group  
(n = 91)
CF group  
(n = 99)
P  
(1 vs. 2)
Primary endpoint
MACE (CD + MI + urgent TVR) 20 (10.5%) 4 (4.3%) 16 (16.2%) 0.009
Secondary endpoints
Any TVR 19 (10%) 14 (15.4%) 5 (5%) 0.014
CD 7 (3.7%) 0 (0%) 7 (7%) 0.01
MI 7 (3.7%) 2 (2.2%) 5 (5%) 0.3
Urgent TVR 6 (3.1%) 2 (2.2%) 4 (4%) 0.3
CD + MI 14 (7.4%) 2 (2.2%) 12 (12.1%) 0.009
CA — coronary angiography; CF — clinical follow-up; CD — cardiac death; MACE — major adverse cardiac events; MI — myocardial infarction; 
TVR — target vessel revascularization
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The Kaplan-Meier MACE-free survivals reported 
in Figure 2 shows a statistically better outcome for 
the CA group than CF group (p = 0.013).
At univariate analysis, significant predictors of 
MACE were age (p = 0.003), severe ventricular 
dysfunction (p = 0.015), follow-up modality (CF 
or CA) (p < 0.0001). At multivariable analysis, 
the follow-up modality (CF vs. CA) was the only 
independent predictor of MACE, CA being associ-
ated with a reduced risk (HR 0.13, 95% CI 0.1–0.7, 
p = 0.028).
Discussion
Previous randomized and non-randomized 
trials consistently reported that routine coronary 
angiography at follow-up increased repeat coronary 
revascularization without reduction in MACE, 
although the rate of MI was lower in the routine 
coronary angiography group of the sub-studies of 
Balloon Angioplasty and Anticoagulation Study 
and the TAXUS-IV trial [7–9, 16–18]. Recently the 
Randomized Evaluation of Routine Follow up Coro-
nary Angiography after Percutaneous Coronary 
Interventional Trial (REACT)  has confirmed that 
routine CA after PCI was not associated to clinical 
benefits and early coronary revascularization rates 
were increased within routine CA strategy [19]. 
However, the trial was underpowered to detect 
modest benefits of a routine CA after PCI and in the 
subgroup analyses the routine CA strategy is as-
sociated to a trend with a lower incidence of MACE 
in patients undergoing ULM PCI. Therefore, the 
impact of routine CA strategy in high risk patients, 
such as patients had undergone ULM PCI, in real 
world practice has not been fully evaluated.
The results of the present study show that 
routine CA, despite being not recommended by 
contemporary guidelines, may be appropriate in 
patients undergoing successful complex PCI. In 
particular, patients who underwent PCI on ULM. 
PCI may have a major clinical benefit since an 
early recognition and treatment of restenosis may 
help reduce mortality at follow up. Several stud-
ies have demonstrated the safety and feasibility of 
complex PCI such as ULM PCI and many centers 
currently perform these procedures which are as-
sociated with considerable risk of restenosis and 
adverse clinical outcomes. Yet the most appropriate 
strategy to follow these patients after successful 
revascularization remains debated. Indeed, rou-
tine control angiography is often recommended 
between 6 and 12 months after PCI, but evidence 
in support of this strategy is lacking. Previous stud-
ies have reported that routine control angiography 
after PCI leads to higher rates of repeat interven-
tions, without clear advantages when compared 
with a conservative management in which repeat 
angiography is reserved to patients presenting 
recurrent symptoms or objective sign of myocardial 
ischemia [7, 8, 15, 16] including patients receiving 
ULM PCI [20].
In the present study, the clinical impact of rou-
tine control angiography was evaluated in patients 
undergoing complex PCI, such as revascularization 
for ULM stenosis. The main finding of this study 
is that even if routine control angiography is as-
sociated (as expected) with a higher rate of repeat 
TVR, it appears to improve late outcome since the 
composite of cardiac death, nonfatal MI and urgent 
TVR was significantly reduced. Such findings may 
suggest that “elective” repeat revascularization 
procedures may have a beneficial impact on clinical 
outcomes in high risk patients [21, 22]. In keeping 
with this notion, in a recent study, the evidence of 
asymptomatic restenosis was predictive of 4-year 
mortality [13]. In the same study, which was not 
focused on complex PCI patients, the received 
management (conservative or repeat revasculariza-
tion) did not influence outcome [13]. 
Of note, the results of the present study are 
in contrast with that of another study on most ap-
propriate follow up strategy in undergoing ULM 
PCI. Indeed, Biondi-Zoccai et al. [20] reported no 
Figure 2. Kaplan-Meier major adverse cardiac events-
free survival curves in patients with unprotected left 
main percutaneous coronary intervention undergoing 
coronary angiography (CA) or clinical follow-up (CF). 
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benefit with CA vs. CF. This study has the same 
limitations as the present study as they were both 
retrospective, observational, single center regis-
ter. Importantly, Biondi-Zoccai et al. [20] reported 
a much higher rate of angiographically-driven TVR 
(thus reflecting a different attitude in the manage-
ment of mild restenosis) and including any TVR 
(not just urgent TVR) as a component of primary 
end-point.
Recently a multicenter registry, included 
consecutive patients with a critical lesion of an 
ULM treated with second generation DES, has 
demonstrated that planned angiographic control 
was associated with more TVR but with lower rates 
of cardiovascular death [23]. Although the study 
has a retrospective design, the number of patients 
enrolled has allowed propensity score balancing to 
correct the heterogeneity of the study groups. In 
the present study a similar incidence of TVR was 
found and a similar benefit on prognosis for patients 
with planned angiographic control but presently 
herein, have not completely removed the risk of 
selection bias tending to favor the performance of 
routine angiography in healthier patients, despite 
the multivariate analysis.
Limitations of the study
The major limitation of this study is the ret-
rospective, observational and single center design 
as the choice of follow-up strategy was left to the 
referring physician and/or patient. Therefore, 
differences can be expected in baseline and pro-
cedural characteristics of the groups and multivari-
ate analysis may not have completely eliminated 
the risk of selection bias tending to favor the 
performance of routine angiography in healthier 
patients. Furthermore, the relatively small number 
of patients precludes the possibility of propensity 
score balancing to correct heterogeneity of the 
study groups. The strategy of clinical follow-up 
is related to the referring physician discretion. 
Therefore, selected strategy of clinical follow-up 
and, specifically, the use of non-invasive tests are 
unknown for both study groups. In conclusion, 
the results of this study call for future evaluations 
of the clinical impact of systematic angiographic 
follow-up in patients who have successfully un-
dergone ULM PCI.
Conclusions
The present study evaluated the clinical im-
pact of routine control angiography in patients 
undergoing to PCI revascularization for ULM 
stenosis. The main finding is that even if routine 
control angiography is associated (as expected) 
with a higher rate of repeat TVR, it appears to im-
prove late outcome since the composite of cardiac 
death, nonfatal MI and urgent TVR was signifi-
cantly reduced, suggesting that “elective” repeat 
revascularization procedures may have a beneficial 
impact on clinical outcomes in high risk patients. 
The present findings are hypothesis generating 
and need to be confirmed by adequately powered, 
randomized and controlled trials.
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